Health Care • Biotechnology: Pharmaceutical Preparations
$371.56 ▼ -1.80
(-0.48%)
MKT CAP: $42.25B • VOL: 268.1K
52W L $254 52W H $389
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$312
MEDIAN
$416
MEAN
$424
HIGH
$505
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ONC TAPE
ONC // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $449.59 | $427.29 | 2025-02-14 | $338.12 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $468.17 | $438.44 | 2025-02-06 | $349.27 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $423.58 | $408.72 | 2025-01-29 | $356.70 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $378.99 | — | 2025-01-17 | $364.13 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $326.97 | $352.98 | 2025-01-09 | $330.69 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $442.16 | $386.42 | 2024-12-18 | $323.26 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $360.41 | $375.28 | 2024-12-04 | $345.55 | -4.3% | 48% | C |